Outcome of research on mRNA vaccine impact on innate immunity by end of 2025?
Confirmed suppression • 25%
No suppression found • 25%
Inconclusive results • 25%
Suppression only in specific cases • 25%
Peer-reviewed scientific publications
Study of 99 Million Vaccinated Finds 610% Increased Myocarditis Risk and Other Adverse Events Post mRNA COVID-19 Vaccines
Jan 14, 2025, 03:43 PM
A large-scale study involving 99 million vaccinated individuals has confirmed an increased risk of adverse events following mRNA-based COVID-19 vaccinations, including a 610% increased risk of myocarditis. Additionally, a descriptive analysis of 241 individuals who self-reported a post-vaccination syndrome (PVS) after receiving the COVID-19 vaccine showed that the most common symptoms were exercise intolerance (71%), excessive fatigue (69%), numbness (63%), brain fog (63%), and neuropathy (63%). These individuals reported a median of 20 symptoms and tried a median of 20 treatments, indicating a significant health burden. The study also highlighted the detection of recombinant spike protein in the plasma of vaccinated individuals, suggesting systemic distribution of the vaccine's components. Furthermore, research has indicated that mRNA vaccines may impair innate immunity by suppressing type I interferon responses and could potentially increase the risk of infectious diseases and cancer due to disturbances in regulatory control of protein synthesis and cancer surveillance.
View original story
Minor issues found • 25%
No issues found • 25%
Undetermined • 25%
Significant issues found • 25%
Positive safety and immunogenicity results • 25%
Study inconclusive • 25%
Negative immunogenicity results • 25%
Negative safety results • 25%
Successful with moderate efficacy • 25%
Trial inconclusive • 25%
Successful with high efficacy • 25%
Unsuccessful • 25%
Successful without FDA approval • 25%
Successful with FDA approval • 25%
Trial ongoing • 25%
Unsuccessful • 25%
Mostly positive • 25%
Unchanged • 25%
Mostly negative • 25%
Mixed • 25%
Unsuccessful • 25%
Successful with FDA approval • 25%
Ongoing • 25%
Successful without FDA approval • 25%
Unsuccessful • 25%
Delayed • 25%
Successful without FDA approval recommendation • 25%
Successful with FDA approval recommendation • 25%
Trials delayed • 25%
Successful with no major issues • 25%
Successful with minor issues • 25%
Unsuccessful • 25%
Enhanced safety protocols recommended • 25%
Comprehensive overhaul of vaccine policies • 25%
Some vaccines recommended for elimination • 25%
No changes recommended • 25%
Successful • 25%
Unsuccessful • 25%
Not Completed • 25%
Partially Successful • 25%
No impact • 25%
Positive impact • 25%
Significant negative impact • 25%
Minor negative impact • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Brain fog • 25%
Numbness • 25%
Exercise intolerance • 25%
Excessive fatigue • 25%